article thumbnail

SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]

Annals of Family Medicine

Context Two thirds of diabetes patients complicated with hypertension, and comorbidity increase 4-fold risk of atherosclerotic cardiovascular disease (ASCVD). Population Studied individuals with comorbidity of hypertension and type 2 diabetes. Outcome Measures Changes of China-PAR score and cardiovascular hospitalization events.

article thumbnail

DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes

Physician's Weekly

WEDNESDAY, June 18, 2025 (HealthDay News) — The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes, according to a study published online June 9 in JAMA Internal Medicine. Pilla, M.D., Pilla, M.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Key Facts GPs Should Know About GLP-1 Analogs

Family Medicine Initiative

Cardiovascular Events The SELECT trial 1 randomized 17,604 patients with preexisting CVD and overweight/obesity. Relative risk for cardiovascular events was reduced by 19% (RRR), while the absolute risk was reduced by 1.5% 5 In March 2024, Novo Nordisk announced that 24% less CKD-related events occurred in the intervention group.

Diabetes 130
article thumbnail

Diabetes drugs associated with fewer adverse cardiac events in older veterans

Medical Xpress

GLP1 receptor agonists—a class of diabetes medications—are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

article thumbnail

What to Expect at the ADA 85th Scientific Sessions: Obesity, Nutrition, Prevention, and More

Physician's Weekly

The ADA’s 85th Scientific Sessions will highlight breakthroughs in obesity and diabetes care, including GLP-1 therapies, tech advances, and prevention tools. The event will convene more than 11,000 global researchers, clinicians, and industry leaders to highlight major strides in research and real-world treatment. Roughly 42% (109.9

article thumbnail

Revisiting the Advantages of aSOAP Notes: The Best of the Paper Chart and Old School Photography

A Country Doctor Writes

I don’t really need the details in order to know how to consider this patient’s risk for future cardiac events. 72 year old female with diabetes and heavy atherosclerotic burden presents with two weeks of increased dyspnea and weight gain as well as increased thirst and episodes of blurry vision. In-house HbA1c is 9.

article thumbnail

FDA Approves Polypill Widaplik for Hypertension

Physician's Weekly

The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure. Widaplik is not to be coadministered with aliskiren in patients with diabetes, and a boxed warning indicates discontinuation of Widaplik during pregnancy.